$COGT
Cogent Biosciences, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020052593 Filed on November 09, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $312.0K $1.020M $3.138M
YoY Change -69.41% -50.07% 88.36%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.600M $2.720M $3.060M
YoY Change 105.88% 14.77% 54.55%
% of Gross Profit
Research & Development $5.003M $10.34M $10.62M
YoY Change -51.59% 0.81% 16.34%
% of Gross Profit
Depreciation & Amortization $120.0K $320.0K $330.0K
YoY Change -62.5% -3.03% 0.0%
% of Gross Profit
Operating Expenses $5.003M $10.34M $10.62M
YoY Change -51.59% 0.81% 16.34%
Operating Profit -$57.20M -$12.04M -$10.54M
YoY Change 375.23% 13.8% 11.67%
Interest Expense $20.00K $30.00K $30.00K
YoY Change -33.33% -92.68% -88.46%
% of Operating Profit
Other Income/Expense, Net $7.216M $113.0K $25.00K
YoY Change 6285.84% -72.3% -93.99%
Pretax Income -$49.98M -$11.92M -$10.52M
YoY Change 319.3% 17.21% 16.63%
Income Tax
% Of Pretax Income
Net Earnings -$49.98M -$11.92M -$10.52M
YoY Change 319.21% 17.26% 16.55%
Net Earnings / Revenue -16020.19% -1168.92% -335.12%
Basic Earnings Per Share -$0.39 -$0.34
Diluted Earnings Per Share -$5.074M -$0.39 -$0.34
COMMON SHARES
Basic Shares Outstanding 30.66B 30.51B
Diluted Shares Outstanding 30.66B 30.51B

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $129.4M $45.90M $55.90M
YoY Change 181.92% -47.3% -40.78%
Cash & Equivalents $130.7M $45.88M $55.86M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $4.000M $1.200M $1.200M
YoY Change 233.33% 20.0% -20.0%
Inventory
Prepaid Expenses
Receivables $0.00 $880.0K $1.492M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $133.4M $47.98M $58.60M
YoY Change 178.04% -46.39% -39.66%
LONG-TERM ASSETS
Property, Plant & Equipment $5.200M $2.170M $2.632M
YoY Change 139.63% -39.94% -33.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M $847.0K $846.0K
YoY Change 53.48% 102.15% 101.91%
Total Long-Term Assets $6.500M $9.906M $10.71M
YoY Change -34.38% 87.37% 90.84%
TOTAL ASSETS
Total Short-Term Assets $133.4M $47.98M $58.60M
Total Long-Term Assets $6.500M $9.906M $10.71M
Total Assets $139.9M $57.88M $69.31M
YoY Change 141.69% -38.93% -32.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $600.0K $1.594M $1.660M
YoY Change -62.36% 98.51% -0.24%
Accrued Expenses $5.700M $7.000M $6.400M
YoY Change -18.57% 100.0% 236.84%
Deferred Revenue $14.72M $15.18M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.10M $24.43M $24.31M
YoY Change -17.72% -7.41% -2.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.700M $4.800M $5.200M
YoY Change -22.92% 433.33% 333.33%
Total Long-Term Liabilities $3.700M $4.800M $5.200M
YoY Change -22.92% 433.33% 333.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.10M $24.43M $24.31M
Total Long-Term Liabilities $3.700M $4.800M $5.200M
Total Liabilities $23.80M $29.26M $29.55M
YoY Change -18.66% 7.36% 13.44%
SHAREHOLDERS EQUITY
Retained Earnings -$126.2M -$114.3M
YoY Change 51.21% 55.92%
Common Stock $154.8M $154.0M
YoY Change 2.52% 2.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$22.17M $28.62M $39.76M
YoY Change
Total Liabilities & Shareholders Equity $139.9M $57.88M $69.31M
YoY Change 141.69% -38.93% -32.53%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$49.98M -$11.92M -$10.52M
YoY Change 319.21% 17.26% 16.55%
Depreciation, Depletion And Amortization $120.0K $320.0K $330.0K
YoY Change -62.5% -3.03% 0.0%
Cash From Operating Activities -$10.26M -$10.21M -$11.34M
YoY Change 0.49% 34.7% 43.36%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $0.00
YoY Change -122.22% -100.0%
Acquisitions
YoY Change
Other Investing Activities $8.420M $200.0K $8.000M
YoY Change 4110.0% -98.0% -119.52%
Cash From Investing Activities $8.420M $220.0K $8.000M
YoY Change 3727.27% -97.78% -119.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 109.9M 0.000 100.0K
YoY Change -100.0% -99.86%
NET CHANGE
Cash From Operating Activities -10.26M -10.21M -11.34M
Cash From Investing Activities 8.420M 220.0K 8.000M
Cash From Financing Activities 109.9M 0.000 100.0K
Net Change In Cash 108.1M -9.990M -3.240M
YoY Change -1181.88% -498.01% -115.41%
FREE CASH FLOW
Cash From Operating Activities -$10.26M -$10.21M -$11.34M
Capital Expenditures $20.00K $0.00
Free Cash Flow -$10.23M -$11.34M
YoY Change 36.58% 50.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
cogt Research And Development Expense Acquired In Progress
ResearchAndDevelopmentExpenseAcquiredInProgress
46910000
us-gaap Costs And Expenses
CostsAndExpenses
78614000
us-gaap Costs And Expenses
CostsAndExpenses
41629000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7871000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34418000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12036000
us-gaap Operating Income Loss
OperatingIncomeLoss
-70743000
CY2019Q4 cogt Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
7131000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33355000
us-gaap Investment Income Interest
InvestmentIncomeInterest
73000
us-gaap Investment Income Interest
InvestmentIncomeInterest
206000
CY2020Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
7463000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 cogt Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
5535000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9000000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1020000
CY2020Q3 cogt Contingent Value Right Liability Current
ContingentValueRightLiabilityCurrent
11959000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5003000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
312000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
57511000
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7665763
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7665763
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10677285
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10677285
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12074000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8274000
CY2020Q3 cogt Research And Development Expense Acquired In Progress
ResearchAndDevelopmentExpenseAcquiredInProgress
46910000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
870000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7393000
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
13056000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2721000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5598000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-57199000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
23000
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
31000
CY2020Q3 cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
509000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7216000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
113000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7273000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-49983000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-11923000
us-gaap Net Income Loss
NetIncomeLoss
-63470000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.07
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.56
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.56
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9850530
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7665281
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8392741
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49983000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19630000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7211000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10335000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
7470000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
82000
CY2020Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
239000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
239000
cogt Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
509000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
288000
us-gaap Net Income Loss
NetIncomeLoss
-34130000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.49
CY2019Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
82000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7604688
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
12000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
12000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11923000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63470000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34118000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
35000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
262000
CY2020Q1 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
808000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
507000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6094000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
25702000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
62000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
19241000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
335000
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
13000
CY2020Q3 us-gaap Dividends Common Stock
DividendsCommonStock
11450000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3512000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
726000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-11691000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
49290000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
97000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
885000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-10516000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
788000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
28623000
us-gaap Profit Loss
ProfitLoss
-63470000
us-gaap Profit Loss
ProfitLoss
-34130000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
703000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
979000
us-gaap Share Based Compensation
ShareBasedCompensation
5151000
us-gaap Share Based Compensation
ShareBasedCompensation
2399000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-2000
cogt Noncash Consideration Received From Customer
NoncashConsiderationReceivedFromCustomer
808000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
44812000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
55000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2000000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-788000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2769000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
476000
cogt Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-239000
cogt Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1016000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-427000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
428000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2544000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
75000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1596000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1167000
cogt Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-353000
cogt Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
-1092000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1315000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3232000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26484000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33069000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
677000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5679000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
320000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
204000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
8100000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
22988000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
108000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8420000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23172000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
98907000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10670000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
435000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
48000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
110060000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
91996000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9789000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38679000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56926000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
130675000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47137000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, the valuation of the contingent value right (&#8220;CVR&#8221;) liability and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. <font style="color:#000000;">The extent to which the COVID-19 pandemic may directly or indirectly impact its business, financial condition, and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there is not a material impact to its condensed consolidated financial statements as of and for the three and nine months ended September&#160;30, 2020; however, actual results could differ from those estimates and there may be changes to its estimates in future periods.</font></p>
CY2020Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
CY2020Q1 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
43
CY2019 cogt Deficiency Letter From Listing Qualifications Department Notifying Period
DeficiencyLetterFromListingQualificationsDepartmentNotifyingPeriod
P30D
CY2019Q4 cogt Minimum Bid Price Of Common Stock
MinimumBidPriceOfCommonStock
1.00
CY2019 cogt Initial Period To Regain Compliance With Minimum Bid Price Rule
InitialPeriodToRegainComplianceWithMinimumBidPriceRule
P180D
cogt Reduction To Accrued Expenses And Related Research And Development Expense
ReductionToAccruedExpensesAndRelatedResearchAndDevelopmentExpense
800000
CY2020Q3 cogt Reduction To Accrued Expenses And Related Research And Development Expense
ReductionToAccruedExpensesAndRelatedResearchAndDevelopmentExpense
800000
CY2020Q3 us-gaap Share Price
SharePrice
8.80
CY2019Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1098000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2500000
CY2020Q3 cogt Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2310000
CY2019Q4 cogt Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2987000
CY2020Q3 cogt Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
284000
CY2019Q4 cogt Accrued External Manufacturing Cost Current
AccruedExternalManufacturingCostCurrent
750000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1843000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
894000
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5535000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7131000
CY2020Q3 cogt Preferred Stock Including Temporary Equity Shares Authorized
PreferredStockIncludingTemporaryEquitySharesAuthorized
10000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42390225
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3512000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
788000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5151000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2399000
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-04-30
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The Company’s option to extend for an additional five-year term.
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
900000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
900000
us-gaap Operating Lease Cost
OperatingLeaseCost
1366000
us-gaap Variable Lease Cost
VariableLeaseCost
693000
us-gaap Sublease Income
SubleaseIncome
239000
us-gaap Lease Cost
LeaseCost
1820000
us-gaap Operating Lease Payments
OperatingLeasePayments
2137000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M29D
CY2020Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0950
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
594000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2424000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2497000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
841000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6356000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-49983000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11923000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-63470000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34130000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
41499610
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1165997
CY2020Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2019Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2020Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
CY2020Q3 us-gaap Severance Costs1
SeveranceCosts1
900000
us-gaap Severance Costs1
SeveranceCosts1
2700000
us-gaap Payments For Restructuring
PaymentsForRestructuring
2603000
us-gaap Restructuring Charges
RestructuringCharges
2676000
CY2020Q3 us-gaap Restructuring Reserve
RestructuringReserve
73000

Files In Submission

Name View Source Status
0001564590-20-052593-index-headers.html Edgar Link pending
0001564590-20-052593-index.html Edgar Link pending
0001564590-20-052593.txt Edgar Link pending
0001564590-20-052593-xbrl.zip Edgar Link pending
cogt-10q_20200930.htm Edgar Link pending
cogt-20200930.xml Edgar Link completed
cogt-20200930.xsd Edgar Link pending
cogt-20200930_cal.xml Edgar Link unprocessable
cogt-20200930_def.xml Edgar Link unprocessable
cogt-20200930_lab.xml Edgar Link unprocessable
cogt-20200930_pre.xml Edgar Link unprocessable
cogt-ex105_462.htm Edgar Link pending
cogt-ex107_461.htm Edgar Link pending
cogt-ex311_6.htm Edgar Link pending
cogt-ex312_7.htm Edgar Link pending
cogt-ex321_9.htm Edgar Link pending
cogt-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending